Skip to Main Content

Paper Details

NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer.
Cancer Cell
36
2022
CD8, CD8 T cells, HLA, HLA-, HLA-ABC, HLA-E, NKG2A, NKG2A CD8 T cells, NKG2A PD-1 CD8 T cells, PD-1, PD-1 CD8 T cells, PD-L1, Programmed cell death protein 1, T cell, T cell receptor, T cells, TCR, bladder cancer, bladder tumors, exhausted, human, human leukocyte antigen, human leukocyte antigen (HLA) class I-deficient, programmed death-ligand 1, tumors
Author NameAffiliation
Sudeh IzadmehrTisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Kristin G BeaumontCenter for Advanced Genomics Technology, Icahn School of Medicine at Mount Sinai
Ying-Chih WangCenter for Advanced Genomics Technology, Icahn School of Medicine at Mount Sinai
Mihaela SkobeTisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Seunghee Kim-SchulzeThe Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai
Seunghee Kim-SchulzeThe Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai
Robert SebraCenter for Advanced Genomics Technology, Icahn School of Medicine at Mount Sinai, USA Black Family Stem Cell Institute
Robert SebraCenter for Advanced Genomics Technology, Icahn School of Medicine at Mount Sinai, USA Black Family Stem Cell Institute
Yuko YukiFrederick National Laboratory for Cancer Research
Mary CarringtonFrederick National Laboratory for Cancer Research, USA Ragon Institute of MGH
Mary CarringtonFrederick National Laboratory for Cancer Research, USA Ragon Institute of MGH
Ira Mellman
Matthew D GalskyTisch Cancer Institute, Icahn School of Medicine at Mount Sinai
  • 1 - 13

Datasets

Release 1.2